☆ 4.6 Article

Discovery of VIP236, an αvβ3-Targeted Small-Molecule-Drug Conjugate with Neutrophil Elastase-Mediated Activation of 7-Ethyl Camptothecin Payload for Treatment of Solid Tumors

CANCERS (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Oncology

Payload diversification: a key step in the development of antibody-drug conjugates

Louise Conilh et al.

Summary: Antibody-drug conjugates (ADCs) combine monoclonal antibodies' selectivity with cytotoxic payloads, and recent success in ADC development includes unconventional payloads with differentiated mechanisms of action. Future developments in the ADC field will focus on diversification of payloads, as seen in the growing number of preclinical and clinical unconventional payload-conjugated ADCs. This review provides an overview of validated, forgotten, and newly developed payloads with different mechanisms of action.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2023)

添加到收藏夹

Review Oncology

Optimizing the safety of antibody-drug conjugates for patients with solid tumours

Paolo Tarantino et al.

Summary: Improvements in the design of antibody-drug conjugates (ADCs) have reshaped the treatment of advanced-stage solid tumours, but toxicities of ADCs are still a concern. Ongoing efforts are being made to enhance the safety of ADCs, including optimizing dose and treatment schedule, modifying ADC components, identifying predictive biomarkers for toxicities, and developing innovative diagnostic tools.

NATURE REVIEWS CLINICAL ONCOLOGY (2023)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Antibody-drug conjugates come of age in oncology

Charles Dumontet et al.

Summary: Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the potency of cytotoxic agents. The technology to develop these agents has improved in past years, but toxicity remains a key issue. This Review provides a broad overview of the recent advances and challenges in ADC development for cancer treatment.

NATURE REVIEWS DRUG DISCOVERY (2023)

添加到收藏夹

Article Chemistry, Multidisciplinary

RGD Peptidomimetic MMAE-Conjugate Addressing Integrin αVβ3-Expressing Cells with High Targeting Index

Jannik Paulus et al.

Summary: A library of sulfonamide-modified RGD mimetics with high affinity for integrin alpha(V)beta(3) was synthesized. The best structure was selected and conjugated with a cleavable linker and the drug MMAE to form a SMDC. The resulting SMDC showed high affinity and selectivity for alpha(V)beta(3).

CHEMISTRY-A EUROPEAN JOURNAL (2023)

添加到收藏夹

Article Chemistry, Medicinal

Dual intra- and extracellular release of monomethyl auristatin E from a neutrophil elastase-sensitive antibody-drug conjugate

Imene Ait Mohamed Amar et al.

Summary: ADCs are targeted therapies in oncology, combining a highly potent drug conjugated onto a monoclonal antibody via a linker for selective drug delivery to tumor sites. This study developed a cleavable linker with a dual intra- and extracellular drug release mechanism, providing a new pathway for the design of novel ADCs.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2022)

添加到收藏夹

Article Oncology

A Small Molecule-Drug Conjugate (SMDC) Consisting of a Modified Camptothecin Payload Linked to an αVss3 Binder for the Treatment of Multiple Cancer Types

Hans-Georg Lerchen et al.

Summary: In order to reduce the toxic effects on normal cells, a novel compound VIP236 was designed to specifically target cancer cells and release a cytotoxic drug near the tumor cells using an enzyme. VIP236 has shown promising results in killing tumor cells and minimizing toxicity in mouse models.

CANCERS (2022)

添加到收藏夹

Article Chemistry, Multidisciplinary

Synthesis and Evaluation of a Non-Peptide Small-Molecule Drug Conjugate Targeting Integrin αVβ3

Jannik Paulus et al.

Summary: In this study, a linear RGD mimetic targeting integrin alpha(V)beta(3) was synthesized as a small-molecule drug conjugate (SMDC), showing high activity in inhibiting cell adhesion but low cytotoxicity compared to reference compounds. The influence of integrin binding on antiproliferative activity was also demonstrated.

FRONTIERS IN CHEMISTRY (2022)

添加到收藏夹

Article Oncology

The Peptide-Drug Conjugate TH1902: A New Sortilin Receptor-Mediated Cancer Therapeutic against Ovarian and Endometrial Cancers

Jean-Christophe Currie et al.

Summary: Tumor heterogeneity, drug resistance, and systemic toxicity are major concerns in the treatment of gynecological cancers. This study investigated the anticancer properties of the peptide-docetaxel conjugate TH1902, which targets the SORT1 receptor, in ovarian and endometrial cancers. The results showed that TH1902 had better efficacy and fewer side effects compared to traditional therapies, making it a promising treatment option for SORT1-positive gynecological cancers.

CANCERS (2022)

添加到收藏夹

Article Medicine, General & Internal

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

Shanu Modi et al.

Summary: Trastuzumab deruxtecan demonstrated significantly longer progression-free and overall survival compared to physician's choice chemotherapy in patients with HER2-low metastatic breast cancer.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Editorial Material Oncology

The therapeutic window of antibody drug conjugates: A dogma in need of revision

Raffaele Colombo et al.

CANCER CELL (2022)

添加到收藏夹

Article Chemistry, Medicinal

Discovery of BT8009: A Nectin-4 Targeting Bicycle Toxin Conjugate for the Treatment of Cancer

Gemma E. Mudd et al.

Summary: Bicycle toxin conjugates (BTCs) are a promising new class of molecules that can deliver toxins to tumor cells effectively. BT8009 is a Nectin-4 targeting BTC that has been optimized through chemical optimization. The optimized bicyclic peptide shows highly selective binding to Nectin-4, good plasma stability, and improved physicochemical properties. The optimized bicycle is conjugated to the cytotoxin Monomethyl auristatin E to form the targeted drug conjugate BT8009, which exhibits potent anticancer activity in vivo rodent models.

JOURNAL OF MEDICINAL CHEMISTRY (2022)

添加到收藏夹

Review Biochemistry & Molecular Biology

Antibody drug conjugate: the biological missile for targeted cancer therapy

Zhiwen Fu et al.

Summary: Antibody-drug conjugates (ADCs) combine the highly specific targeting ability of monoclonal antibodies with the potent killing effect of cytotoxic drugs to accurately and efficiently eliminate cancer cells. Since the approval of the first ADC in 2000, 14 ADCs have been marketed worldwide, with over 100 ADC candidates currently in clinical trials. These novel cancer therapeutics, known as biological missiles, are leading the way in targeted cancer therapy.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2022)

添加到收藏夹

Review Oncology

Unlocking the potential of antibody-drug conjugates for cancer therapy

Joshua Z. Drago et al.

Summary: Nine ADCs are currently approved for cancer treatment, with many more in development. Advances in synthetic biochemistry have led to a new generation of ADCs promising improved tissue specificity and cytotoxicity. Despite impressive activity against treatment-refractory cancers, challenges such as systemic toxicity and acquired resistance remain. This review discusses the design, mechanism of action, and limitations of ADCs, proposing strategies to maximize their therapeutic benefit for cancer patients.

NATURE REVIEWS CLINICAL ONCOLOGY (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Antibody-Drug Conjugates-A Tutorial Review

Stephanie Baah et al.

Summary: ADCs are a family of targeted therapeutic agents for cancer treatment, with over 80 currently in clinical development and 11 approved by the FDA. They offer enhanced targeting of cancer cells and reduced toxic side effects compared to traditional approaches, making them an attractive prospect in oncology research.

MOLECULES (2021)

添加到收藏夹

Article Multidisciplinary Sciences

An ultra-high-affinity small organic ligand of fibroblast activation protein for tumor-targeting applications

Jacopo Millul et al.

Summary: OncoFAP is a high-affinity ligand of FAP with pan-tumoral potential, showing strong tumor-targeting performance in nude mouse models. It can also serve as a modular component for nonradioactive therapeutic products, highlighting its potential applications in tumor treatment.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)

添加到收藏夹

Review Oncology

RGD-Binding Integrins Revisited: How Recently Discovered Functions and Novel Synthetic Ligands (Re-)Shape an Ever-Evolving Field

Beatrice S. Ludwig et al.

Summary: Integrins have been extensively researched as therapeutic targets in the past few decades, particularly in the field of cancer. Despite clinical trials not meeting expectations yet, integrins remain promising targets due to their expression on diseased cells. To successfully translate integrin-targeted compounds into clinical practice, refined approaches and innovative treatment strategies need to be explored based on accumulated knowledge of integrin biology.

CANCERS (2021)

添加到收藏夹

Review Medicine, Research & Experimental

Targeting cancer with antibody-drug conjugates: Promises and challenges

Alexis Q. Dean et al.

Summary: ADCs are a rapidly expanding class of biotherapeutics that utilize antibodies to selectively deliver cytotoxic drugs to the tumor site. While there are several ADCs approved by the FDA and many more in clinical trials, challenges remain in expanding their therapeutic index. Advances in manufacturing technology and new bioconjugation platforms are shaping the future development of ADCs.

MABS (2021)

添加到收藏夹

Article Oncology

TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2-metastatic breast cancer

Hope S. Rugo et al.

FUTURE ONCOLOGY (2020)

添加到收藏夹

Article Oncology

MMAE Delivery Using the Bicycle Toxin Conjugate BT5528

Gavin Bennett et al.

MOLECULAR CANCER THERAPEUTICS (2020)

添加到收藏夹

Review Oncology

Integrin Signaling in Cancer: Mechanotransduction, Stemness, Epithelial Plasticity, and Therapeutic Resistance

Jonathan Cooper et al.

CANCER CELL (2019)

添加到收藏夹

Review Chemistry, Medicinal

Small molecule-drug conjugates: A novel strategy for cancer-targeted treatment

Chunlin Zhuang et al.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)

添加到收藏夹

Review Oncology

Are Integrins Still Practicable Targets for Anti-Cancer Therapy?

Begona Alday-Parejo et al.

CANCERS (2019)

添加到收藏夹

Article Oncology

Interleukin-8 promotes integrin β3 upregulation and cell invasion through PI3K/Akt pathway in hepatocellular carcinoma

Fengkai Sun et al.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)

添加到收藏夹

Article Oncology

Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer

Kerry A. Whalen et al.

MOLECULAR CANCER THERAPEUTICS (2019)

添加到收藏夹

Review Chemistry, Multidisciplinary

An αv-RGD Integrin Inhibitor Toolbox: Drug Discovery Insight, Challenges and Opportunities

Richard J. D. Hatley et al.

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2018)

添加到收藏夹

Article Chemistry, Multidisciplinary

Influence of the dissociation rate constant on the intra-tumor distribution of antibody-drug conjugate against tissue factor

Ryo Tsumura et al.

JOURNAL OF CONTROLLED RELEASE (2018)

添加到收藏夹

Article Chemistry, Multidisciplinary

Chemically Defined Antibody- and Small Molecule-Drug Conjugates for in Vivo Tumor Targeting Applications: A Comparative Analysis

Samuele Cazzamalli et al.

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2018)

添加到收藏夹

Article Chemistry, Multidisciplinary

In Vivo Antitumor Activity of a Novel Acetazolamide-Cryptophycin Conjugate for the Treatment of Renal Cell Carcinomas

Samuele Cazzamalli et al.

ACS OMEGA (2018)

添加到收藏夹

Review Environmental Sciences

Mechanisms of DNA Damage, Repair, and Mutagenesis

Nimrat Chatterjee et al.

ENVIRONMENTAL AND MOLECULAR MUTAGENESIS (2017)

添加到收藏夹

Article Multidisciplinary Sciences

Tissue-based map of the human proteome

Mathias Uhlen et al.

SCIENCE (2015)

添加到收藏夹

Article Pathology

Overexpression of integrin αv correlates with poor prognosis in colorectal cancer

Sang Yun Ha et al.

JOURNAL OF CLINICAL PATHOLOGY (2014)

添加到收藏夹

Article Integrative & Complementary Medicine

Berberine Reduces the Metastasis of Chondrosarcoma by Modulating the αvβ3 Integrin and the PKCδ, c-Src, and AP-1 Signaling Pathways

Chi-Ming Wu et al.

EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE (2013)

添加到收藏夹

Article Chemistry, Medicinal

Camptothecins in tumor homing via an RGD sequence mimetic

Domenico Alloatti et al.

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2012)

添加到收藏夹

Article Medicine, Research & Experimental

Targeting Cell Surface Alpha(v)beta(3) Integrin Increases Therapeutic Efficacies of a Legumain Protease-Activated Auristatin Prodrug

Yuan Liu et al.

MOLECULAR PHARMACEUTICS (2012)

添加到收藏夹

Review Medicine, Research & Experimental

RGD-Based Strategies To Target Alpha(v) Beta(3) Integrin in Cancer Therapy and Diagnosis

Fabienne Danhier et al.

MOLECULAR PHARMACEUTICS (2012)

添加到收藏夹

Review Biochemical Research Methods

Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives

Ramesh Mullangi et al.

BIOMEDICAL CHROMATOGRAPHY (2010)

添加到收藏夹

Review Oncology

Integrins in cancer: biological implications and therapeutic opportunities

Jay S. Desgrosellier et al.

NATURE REVIEWS CANCER (2010)

添加到收藏夹

Article Biochemistry & Molecular Biology

An integrin αvβ3-c-Src oncogenic unit promotes anchorage-independence and tumor progression

Jay S. Desgrosellier et al.

NATURE MEDICINE (2009)

添加到收藏夹

Article Biochemistry & Molecular Biology

Neutrophil elastase, proteinase 3 and cathepsin G: Physicochemical properties, activity and physiopathological functions

Brice Korkmaz et al.

BIOCHIMIE (2008)

添加到收藏夹

Article Oncology

Preclinical evaluation of EC145, a folate-Vinca alkaloid conjugate

Joseph A. Reddy et al.

CANCER RESEARCH (2007)

添加到收藏夹

Review Oncology

Neutrophil elastase and cancer

Takashi Sato et al.

SURGICAL ONCOLOGY-OXFORD (2006)

添加到收藏夹

Article Biochemistry & Molecular Biology

Quantification of elastase-like activity in 13 human cancer cell lines and in an immortalized human epithelial cell line by RP-HPLC

K Achilles et al.

BIOLOGICAL CHEMISTRY (2003)

添加到收藏夹

Article Oncology

Sensitive PCR method for the detection and real-time quantification of human cells in xenotransplantation systems

M Becker et al.

BRITISH JOURNAL OF CANCER (2002)

添加到收藏夹

Article Chemistry, Medicinal

Design and optimization of 20-O-linked camptothecin glycoconjugates as anticancer agents

HG Lerchen et al.

JOURNAL OF MEDICINAL CHEMISTRY (2001)

添加到收藏夹

Article Pathology

Integrin αvβ3 expression in colon carcinoma correlates with survival

A Vonlaufen et al.

MODERN PATHOLOGY (2001)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.